8
Participants
Start Date
August 10, 2021
Primary Completion Date
September 29, 2021
Study Completion Date
September 29, 2021
.[14C]-SKI-O-703
Single oral dose of 200 mg (100 μCi in 200 mg salt \[0.5 μCi/mg as salt\], equivalent to 100 μCi in 142 mg active \[0.7 μCi/mg as active\]) of \[14C\]-SKI-O-703 containing approximately 100 μCi of \[14C\]-SKI-O-703 per capsule after an overnight fast.
Labcorp Clinical Research Unit Inc., Madison
Lead Sponsor
Oscotec Inc.
INDUSTRY